Boronated Multifunctional Targeting Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for delivering boron-based drugs, such as bortezomib, to cancer cells face challenges due to unspecific reactivity and off-target toxicity, limiting their therapeutic potential, and existing methods for targeted delivery, like pH-sensitive polymeric carriers and liposomal nanoparticles, have shown reduced activity compared to the free drug.
Innovation Solution
The development of tripodal boronated complexes that can selectively target cancer cells by forming reversible covalent bonds with stimuli-responsive linkers, allowing for controlled release of the therapeutic cargo, such as bortezomib, in intratumoral environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If boron-based drugs are used to treat cancer cells, then therapeutic efficacy is improved, but off-target toxicity increases due to unspecific reactivity
Solution Approach 1:
The drug system is divided into separate functional components: a targeting unit (folate) that directs the complex to cancer cells, a boronated core complex that provides therapeutic activity, and a linker that connects them. This segmentation allows the targeting unit to guide delivery while the drug component remains protected until activation at the target site, reducing off-target toxicity while maintaining therapeutic efficacy.
Solution Approach 2:
A stimuli-responsive linker acts as an intermediary between the targeting unit and the boron-based drug. This linker is designed to be stable during circulation but cleavable under intratumoral conditions (low pH, high glutathione), mediating controlled drug release only at the target site and preventing premature activation that would cause off-target toxicity.
2Adaptability or versatility
If pH-sensitive polymeric carriers are used for targeted delivery, then cancer cell targeting is improved, but drug activity is reduced compared to free drug
Solution Approach 1:
The invention extracts the essential targeting function from complex polymeric carriers and implements it through a simple folate unit attached to a boronated core complex. This minimalistic approach maintains cancer cell targeting capability through folate-receptor binding while avoiding the stability and activity issues associated with complex polymeric and liposomal carriers.
Solution Approach 2:
The system uses a composite structure combining folate (targeting moiety), boronated core complex (therapeutic agent), and stimuli-responsive linker (connection element). This composite design achieves targeted delivery through folate-receptor interaction while maintaining drug activity through proper linker design that enables controlled release without the drawbacks of polymeric carriers.
3Adaptability or versatility
If multifunctional constructs are assembled to deliver therapeutic cargo, then targeted delivery is improved, but synthetic complexity increases
Solution Approach 1:
The invention merges the targeting unit, linker, and drug components into a single integrated multifunctional complex that can be assembled in one pot. The boronated core complex serves as a central platform that simultaneously provides structural support, therapeutic activity, and coordination sites for attaching both the folate targeting unit and the drug payload, simplifying synthesis while maintaining multifunctionality.
Solution Approach 2:
The boronated core complex is designed as a universal platform that can accommodate different targeting units, linkers, and therapeutic cargo molecules. The tridentate ligand structure provides multiple coordination sites that can be functionalized with various components, enabling a single core structure to serve multiple functions and reducing overall synthetic complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These complexes demonstrate high selectivity towards cancer cells, achieving effective intracellular delivery and releasing the therapeutic cargo in a stimulus-responsive manner, enhancing the therapeutic index and reducing off-target toxicity.
Implementation Method 1
forming reversible covalent bonds with stimuli-responsive linkers, allowing for controlled release of the therapeutic cargo
Implementation Method 2
combine the lethality of potent cytotoxic drugs with the targeting ability of specific biomolecules that elicit a high affinity for antigens that are overexpressed in cancer cells
Implementation Method 3
by maintaining the integrity of the conjugate during circulation and by triggering the release of the active drug only upon reaching the target
Data Source
AI summary
Tri-component multi-functional boronated complexes (B-complexes), featuring reversible covalent bonds, are described, which incorporate a drug; a water-soluble moiety (e.g. polyethylene glycol (PEG) chains, cyclodextrins); and a targeting unit. A B-complex core was assembled in one step, and proved to be stable in different biocompatible conditions, such as human plasma, though reversible for example in the presence of glutathione (GSH). This platform enabled the modular construction of the multifunctional conjugates exhibiting high selectivity towards, for example, folate-receptor-positive MDA-MB-231 cancer cells, having an IC50 in the low nanomolar range.